| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1399-0039.2006.00701.X |
| P698 | PubMed publication ID | 17212704 |
| P2093 | author name string | Zhang X | |
| Wang Y | |||
| Chen Y | |||
| Wu C | |||
| Hu Y | |||
| Shi Q | |||
| Sun J | |||
| Zhu Y | |||
| Xu K | |||
| Yu G | |||
| P2860 | cites work | B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 |
| B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells | Q24291070 | ||
| Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production | Q24292957 | ||
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target | Q24559442 | ||
| Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction | Q24673269 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Costimulation of T cells | Q28140955 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2 | Q28202803 | ||
| Expression of programmed death 1 ligands by murine T cells and APC | Q28214264 | ||
| Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer | Q28245751 | ||
| The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses | Q34542227 | ||
| B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. | Q36370918 | ||
| Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. | Q36439488 | ||
| PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells | Q36986702 | ||
| Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells | Q37086718 | ||
| B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression | Q40528021 | ||
| Signals and signs for lymphocyte responses | Q40620206 | ||
| Co-stimulation in T cell responses. | Q41514667 | ||
| B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. | Q47926434 | ||
| Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses | Q48186068 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 19-27 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Tissue Antigens | Q1573131 |
| P1476 | title | PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies | |
| P478 | volume | 69 |
| Q55506755 | Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. |
| Q35769669 | Amniotic fluid stem cells provide considerable advantages in epidermal regeneration: B7H4 creates a moderate inflammation microenvironment to promote wound repair |
| Q35813519 | B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma |
| Q53238384 | B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression. |
| Q54586743 | B7-H6 protein expression has no prognostic significance in human gastric carcinoma. |
| Q40336060 | CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer |
| Q58794926 | EGFR may participate in immune evasion through regulation of B7‑H5 expression in non‑small cell lung carcinoma |
| Q28075698 | Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease? |
| Q35871253 | Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma |
| Q92889954 | Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer |
| Q40082730 | Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. |
| Q26776195 | Gastric cancer: The times they are a-changin' |
| Q41110505 | Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. |
| Q38414152 | Immunotherapy in upper GI malignancies. |
| Q64256264 | Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection |
| Q36919363 | Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression |
| Q26798420 | Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy |
| Q89267506 | Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms |
| Q38649562 | PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence |
| Q92835227 | PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer |
| Q38829062 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial |
| Q26774521 | Personalized medicine in gastric cancer: Where are we and where are we going? |
| Q38369260 | Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis |
| Q53249720 | Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. |
| Q36891533 | Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis |
| Q57167306 | Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer |
| Q37706604 | Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability |
| Q92645904 | Programmed death-1 and PD-1 ligand-1 expression in early onset gastric carcinoma and correlation with clinicopathological characteristics |
| Q55267299 | Role of microRNAs and Exosomes in Helicobacter pylori and Epstein-Barr Virus Associated Gastric Cancers. |
| Q92382425 | Significant function and research progress of biomarkers in gastric cancer |
| Q26779217 | State of the art management of metastatic gastroesophageal cancer |
| Q39733926 | T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract |
| Q36471685 | Targeted therapies in gastric cancer and future perspectives. |
| Q38731943 | Targeted therapies in gastric cancer treatment: where we are and where we are going. |
| Q91654978 | The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives |
| Q38910078 | The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients. |
| Q36205148 | The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients |
| Q34093668 | The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer |
| Q28085398 | Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology |
Search more.